Randomized phase 2 study of concurrent versus sequential pembrolizumab combined with chemoradiation in locally advanced head and neck cancer
Dr, Robert Ferris
A multicenter phase 2 trial in the USA compared concurrent pembrolizumab plus chemoradiation (CRT) versus sequential pembrolizumab after CRT for locally advanced head and neck squamous cell carcinoma. The sequential arm had numerically better outcomes. The authors conclude that CRT with sequential pembrolizumab met criteria for further study.
